Navigation Links
Genta Incorporated to Present Multiple Abstracts at the Annual,Meeting of the American Society of Clinical Oncology

BERKELEY HEIGHTS, N.J., May 25, 2007 /PRNewswire-FirstCall/ -- Genta Incorporated announced that several abstracts featuring its oncology products, Genasense(R) (oblimersen sodium) Injection, and Ganite(R) (gallium nitrate injection), will be presented at the 43rd annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2007. The abstracts include the following:

    -- LDH is a Prognostic Factor in Stage IV Melanoma Patients but is a

       Predictive Factor only for Bcl-2 Antisense Treatment Efficacy: Re-

       analysis of GM301 and EORTC18951 Randomized Trials.  Abstract #8552;

       Sunday, June 3, 2007.

    -- A Phase III Randomized Trial of Intensive Induction and Consolidation

       Chemotherapy +/- Oblimersen (Genasense; G3139), a Pro-Apoptotic Bcl-2

       Antisense Oligonucleotide, in Untreated Acute Myeloid Leukemia Patients

       greater than or equal to 60 Years Old: Cancer and Leukemia Group B

       (CALGB) Study 10201. Abstract #7012; Saturday, June 2, 2007.

    -- GaRD Study: Gallium, Rituximab, and Dexamethasone for Relapsed NHL.

       Poster #Y1, Abstract #8079; Saturday, June 2, 2007.

    -- Oblimersen (Genasense(R)) Can Be Administered by Subcutaneous and Brief

       Intravenous Infusion: Clinical Pharmacokinetics and Pharmacodynamics in

       Patients with Advanced Cancer. (Publication)

    -- Long-term Administration of Oblimersen plus Chemotherapy: An Analysis

       of Safety in Patients with Solid Tumors and Hematologic Cancers.

       (Publication)

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblim
'"/>




Page: 1 2 3

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
(Date:9/2/2015)... , Sept. 2, 2015 Research and Markets ( ... Regulatory Affairs in China (Basel, Switzerland - November 26-27, 2015)" ... will provide a detailed overview of the key areas of ... Hong Kong , Macau ... - All important aspects of gaining and maintaining ...
(Date:9/2/2015)... -- Seeger Weiss LLP is reporting that Zimmer Holdings Inc.,s ... 2015. Since the product was approved ... NexGen knee implant surpassed FDA investigation and mandatory product ... that the product is substantially similar to a preexisting ... In 2001, Zimmer began distributing High ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6x789c/new_eu ) has announced the ... UK - November 16-17, 2015)" conference to their ... concerning Pharmacovigilance are a major departure in terms of ... . The intention of the course is to ... they overlap and fit together and what Companies need ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
(Date:9/3/2015)... ... 03, 2015 , ... Doctor Kayode Sotonwa can be counted on ... perspective on internal medicine keeps patients happy and healthy, something that is important to ... the season, but even more so in the fall, when holiday eating and seasonal ...
(Date:9/2/2015)... ... September 03, 2015 , ... Leah ... among the most influential leaders in healthcare, will offer the keynote address at ... place October 15-16, 2015, in Palm Harbor, Florida, at the Innisbrook Resort and ...
(Date:9/2/2015)... ... 02, 2015 , ... The CRISPR-Cas9 system introduces double-strand DNA breaks ... nuclease with either a chimeric single guide RNA (sgRNA) or two short RNAs (a ... RNA (sgRNA or crRNA) to create a break in the target DNA that causes ...
(Date:9/2/2015)... ... ... to an article published August 12 by International Business Times, a new bill ... grand juries in cases meant to decide if a police officer used deadly or excessive ... in Ferguson and New York City that absolved police officers of charges in the deaths ...
(Date:9/2/2015)... Lauderdale, FL (PRWEB) , ... September 02, 2015 ... ... for Amgen’s Blincyto® (blinatumomab) – in the news recently following a decision by ... hospitalized Medicare patients – is likely to average approximately $71,000 or roughly 40% ...
Breaking Medicine News(10 mins):Health News:Doctor Kayode Sotonwa Highlights Expert Tips for Staying in Shape This Fall 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4
... study to identify the composition of bacterial populations on the ... Skin, which// is the largest organ in our body harbors ... previously. Researchers said that it appears that the skin, is ... quite novel. ,Researchers found evidence for 182 species ...
... during pregnancy could lead to diabetes and cardio vascular ... women. Among them, those who had a high BP ... atherosclerosis than their counterparts who had a normal BP. ... latest issue of ‘Hypertension’ suggests that calcification of the ...
... latest Government data, there is an alarming rise in suicides ... linked to the plummeting sale of// antidepressants. ,This ... also indicated that youth in their late teens resorted to ... Administration had issued a black box warning on the antidepressants ...
... conducted by Robert Wilson of Rush University Medical Centre of Chicago ... Alzheimer’s like// Dementia. People who are single or socially secluded are ... their life. ,According to this study, a group of ... age group of 80 for a period of four years. A ...
... Worldwide describes a lawsuit from CSPI -Center for Science in ... claims of their new drink. ,According to the ... more calories and hence, an aid to calorie ... soft drink is laced with EGCG or epigallocatechin gallate which ...
... pain in the jaw may be a sign of a heart ... Uruguay.// ,The symptoms are however often overlooked, and especially ... tooth or jaw ache without chest pains, the study said. ... were asked to indicate on a body chart where they experienced ...
Cached Medicine News:Health News:Human Skin Harbors Many More Types of Bacteria 2Health News:Human Skin Harbors Many More Types of Bacteria 3Health News:Human Skin Harbors Many More Types of Bacteria 4Health News:Human Skin Harbors Many More Types of Bacteria 5Health News:Support Claims With Science Not Magic, Beverage Owners Warned 2
Detection of Malarial antigen in Human whole blood....
Malaria ( P. Falciparum ) Whole Blood Strip / Cassette...
This is an antigen-capture assay intended for the detection of histidine-rich protein ll (PfHRP-ll), which is released from Malaria-infected red blood cells....
OptiMAL is a malaria test, for diagnosis and therapy control of an infection by Plasmodium species (Malaria)....
Medicine Products: